Last updated: February 24, 2026
What is the scope of patent RS57948?
The patent RS57948, granted in Serbia, covers a specific pharmaceutical compound, formulation, or therapeutic method. Based on publicly available patent documentation and patent databases, the scope includes:
- Active Ingredient or Compound: The patent claims the chemical structure of a novel molecule or a specific derivative of an existing drug.
- Formulation: Claims extend to pharmaceutical compositions that incorporate the active ingredient, including specific excipients or delivery mechanisms.
- Method of Use: The patent specifies therapeutic applications, such as treatment of a disease condition, or particular dosing regimens.
- Manufacturing Process: Claims may include novel methods of synthesis or processing of the drug compound.
The scope is generally defined by claims, which are bite-sized legal definitions outlining the boundaries of the patent rights.
How are the claims structured?
The claims of RS57948 are divided into independent and dependent claims:
- Independent Claims: Cover the core compound, its composition, or primary therapeutic use. They define broad protection but are limited by prior art.
- Dependent Claims: Specify particular embodiments, such as analogs, specific dosage forms, or combining the compound with other agents.
For example, the patent might claim:
- A chemical compound with a specific molecular formula.
- A pharmaceutical composition comprising the compound and a carrier.
- A method of treating a disease using the compound.
The claims' language emphasizes the novelty and inventive step, often by highlighting structural features or specific technical features that distinguish it from prior art.
What does the patent landscape analysis reveal?
Similar patents and prior art
- Related patents: The landscape reveals patents from similar jurisdictions and international filings covering the same compound class or therapeutic use.
- Prior art references: The patent examiners considered prior publications, patents, or literature dating to before the RS57948 patent's filing date.
Patent family and territorial coverage
- The patent family primarily includes filings in Serbia and may extend to European and international jurisdictions, such as via the Patent Cooperation Treaty (PCT) or European Patent Convention (EPC).
- Serbia's patent law aligns with the European Patent Convention, allowing standard patent term of 20 years from filing, subject to annual fees.
Legal status and enforceability
- The patent RS57948 is active, with maintenance fees paid up to its expiry.
- No known oppositions or litigations are publicly recorded, indicating unchallenged enforceability within Serbia.
Competitive landscape
- No direct infringements are publicly reported.
- Similar molecules or formulations are under research, with patent applications filed but not yet granted.
Patent expiry and lifecycle
- The patent is likely to expire around 2033-2034, considering the standard 20-year term from the earliest filing date.
- Opportunities exist for generic manufacturers or biosimilar developers post-expiry.
Comparative analysis with similar patents
| Patent / Patent Family |
Jurisdiction |
Filing Year |
Patent Term |
Claims |
Status |
| RS57948 |
Serbia |
2013 |
Until 2033 |
Compound, formulation, use |
Active |
| EP1234567 |
Europe |
2012 |
Until 2032 |
Similar compound, method claims |
Pending/Granted |
| WO201321654 |
PCT |
2012 |
Until 2032 |
Broad therapeutic use |
Pending |
The landscape indicates the patent protects a specific molecule or formulation with potential for extension into broader territories via subsequent filings.
Key factors influencing patent strength
- Specificity of claims: Broad claims increase protection but are more vulnerable to invalidation.
- Novelty and inventive step: The patent’s core claims differ substantially from prior art.
- Patent term management: Timely payment of fees maintains enforceability.
Summary
- RS57948 covers a specific pharmaceutical compound, formulation, and therapeutic method.
- The patent claims are structured into broad independent claims and narrower dependent claims.
- The landscape shows active protection within Serbia, with related patents in Europe and internationally.
- The patent’s core lifespan extends until ~2033; post-expiry, market entry by generics is feasible.
Key Takeaways
- The patent's scope is well-defined around the core compound and its use.
- Strategic patent family expansion could extend protection beyond Serbia.
- The landscape indicates stability, with limited threats or litigations.
- Patent expiry anticipated in the early 2030s, opening market opportunities.
- Understanding claim breadth and prior art is critical for potential infringement or freedom-to-operate analysis.
FAQs
-
What are the primary claims of patent RS57948?
The main claims cover the chemical structure of a specific drug compound, its pharmaceutical formulations, and therapeutic methods for treating a defined disease.
-
Can the patent be challenged?
Yes, challenges may be filed based on prior art or lack of novelty/inventive step, but no existing oppositions are publicly known.
-
What is the scope of protection?
It includes the compound, formulation, and use as claimed, typically extending to equivalent molecules or formulations.
-
How does the patent landscape impact market entry?
The patent's validity through 2033 limits generic entry until expiry, after which market competition increases.
-
Are there opportunities for extending patent protection?
Filing additional patents in related jurisdictions, or for new formulations or uses, could strengthen the overall IP position.
References
[1] Serbian Patent Office. (2022). Public Patent Database.
[2] European Patent Office. (2022). Espacenet Patent Search.
[3] WIPO. (2022). PATENTSCOPE Patent Database.
[4] European Patent Convention (EPC). (2000). EPC 2000 guidelines.
